Prevalence of poor lipid control in patients with premature coronary artery disease

Martínez-Sánchez Froylan D1, Jorge-Galarza Esteban1, Posadas-Romero Carlos1

  • 1Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano 1, Sección XVI, C.P. 14080, Tlalpan, Mexico City, Mexico.

Insights

Lipid control is poor in premature coronary artery disease patients, with low adherence and obesity being key factors. Achieving lipid goals requires better treatment adherence and more aggressive statin therapy for these high-risk individuals.

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • Lipid management goals are increasingly stringent for high-risk patients.
  • Premature coronary artery disease (CAD) patients often require comprehensive lipid control.
  • No prior studies have assessed composite lipid goal achievement in premature CAD.

Purpose of the Study:

  • To evaluate lipid control rates in premature CAD patients.
  • To identify factors associated with failure to achieve composite lipid goals.

Main Methods:

  • 1196 patients with premature CAD (men <55, women <65 years) were analyzed.
  • Lipid control was assessed using American Heart Association/American College of Cardiology (non-strict) and American Association of Clinical Endocrinologists (strict) criteria.
  • Data on sociodemographics, diet, and clinical factors were collected.

Main Results:

  • Lipid control was achieved in only 23.0% (non-strict) and 8.9% (strict) of patients.
  • 46.5% (non-strict) and 62.8% (strict) failed to meet any lipid goal.
  • Poor control was linked to treatment adherence <85%, low/moderate-intensity statin use, and obesity.

Conclusions:

  • Lipid control is suboptimal in patients with premature CAD.
  • Low treatment adherence, underutilization of high-intensity statins, and obesity are independently associated with poor lipid control.
  • Enhanced preventive strategies and aggressive pharmacological interventions are crucial for reducing premature CAD burden.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
520
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
771
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
258
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
270
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
230
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
169